Novel methods to determine complement activation in human serum induced by the complex of Dezamizumab and serum amyloid P
| Autor: | Jianhong Ma, John R. White, Qi Liu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
C3a desArg
CP classical pathway IgG immunoglobulin G Biochemistry Classical complement pathway MSD ADCC antibody-dependent cell-mediated cytotoxicity Humans ADCP antibody-dependent cellular phagocytosis mAb monoclonal antibody C3 CDC complement-dependent cytotoxicity Molecular Biology Complement C1q Complement Activation Serum amyloid P component classical complement pathway Complement component 3 biology Chemistry FRET fluorescence resonance energy transfer technology Dezamizumab Antibodies Monoclonal Cell Biology Complement System Proteins Surface Plasmon Resonance MSD meso scale discovery Complement-dependent cytotoxicity Complement system LP lectin pathway Serum Amyloid P-Component Lectin pathway complement method Immunoglobulin G biology.protein MAC membrane attack complex RS reference standard SAP serum amyloid P Complement membrane attack complex SAP HTRF HTRF homogeneous time-resolved fluorescence Research Article |
| Zdroj: | The Journal of Biological Chemistry |
| ISSN: | 1083-351X 0021-9258 |
| Popis: | Lack of simple and robust methods to determine complement activation in human serum induced by antigen-antibody complexes is a major hurdle for monitoring therapeutic antibody drug quality and stability. Dezamizumab is a humanized IgG1 monoclonal antibody that binds to serum amyloid P component (SAP) for potential treatment of systemic amyloidosis. The mechanism of action of Dezamizumab includes the binding of SAP, complement activation through classical pathway, and phagocytosis; however, the steps in this process cannot be easily monitored. We developed two novel methods to determine Dezamizumab-SAP complex-induced complement activation. Complement component 3 (C3) depletion was detected by homogeneous time-resolved fluorescence (HTRF), and C3a desArg fragment, formed after the cleavage of C3 to yield C3a followed by removal of its C-terminal arginine residue, was determined using Meso Scale Discovery (MSD) technology. We found that the presence of both Dezamizumab and SAP was required for complement activation via both methods. The optimal molar ratio of Dezamizumab:SAP was 6:1 in order to obtain maximal complement activation. The relative potency from both methods showed a good correlation to Dezamizumab-SAP-dependent complement component 1q (C1q) binding activity in Dezamizumab thermal-stressed samples. Both SAP and C1q binding, as determined by surface plasmon resonance and the two complement activation potency methods described here, reflect the mechanism of action of Dezamizumab. We conclude that these methods can be used to monitor Dezamizumab quality for drug release and stability testing, and the novel potency methods reported here can be potentially used to evaluate complement activity induced by other antigen-antibody complexes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|